Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners boosted their target price on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

NASDAQ TNXP opened at $0.14 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $22.14. The firm has a 50-day moving average price of $0.16 and a 200 day moving average price of $1.67.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. The business had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. On average, equities research analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.